Twice-daily oral administration1
Not an actual patient.
Recommended administration of Joenja
- 70 mg, orally
- Twice daily, ~12 hours apart
- In adult and pediatric patients ≥12 years of age and weighing ≥45 kg*
Joenja can be taken with or without food.
Advise patients that if a dose is missed by
more than 6 hours, wait and take the next
dose at the usual time.
Advise patients that if vomiting occurs
- Within 1 hour after taking Joenja, take Joenja as soon as possible
- More than 1 hour after taking Joenja, wait and take the next dose at
the usual time
*There is no recommended dosage for pediatric patients 12 years of age and older who weigh less than 45 kg.
Joenja oral tablets can be taken anytime, anywhere1
- Joenja should be taken twice a day, approximately
12 hours apart
About APDS
APDS is a rare, primary
immunodeficiency. Hyperactivity along
the Pl3Kδ signaling pathway disrupts
immune cell balance, causing immune
deficiency and
immune dysregulation.1-4
immunodeficiency. Hyperactivity along
the Pl3Kδ signaling pathway disrupts
immune cell balance, causing immune
deficiency and
immune dysregulation.1-4
About
APDS Assist
This patient support program is
designed specifically for your
patients with APDS.
designed specifically for your
patients with APDS.
References: 1. Joenja (leniolisib). Prescribing information. Pharming Healthcare, Inc; 2023. 2. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971-983. doi:10.1182/blood.2022018546 3. Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866-871. doi:10.1126/science.1243292 4. Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: The
European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol. 2018;9:543. doi:10.3389/
fimmu.2018.00543
European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol. 2018;9:543. doi:10.3389/
fimmu.2018.00543
